^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    basroparib (STP1002)

    i
    Other names: STP1002, STP06 1002, STP06-1002
    Company:
    Dong-A
    Drug class:
    TNKS inhibitor
    Related drugs:
    10ms
    First-In-Human Dose-Escalation Study of STP1002 in Patients With Advanced-Stage Solid Tumors (clinicaltrials.gov)
    P1, N=32, Completed, ST Pharm Co., Ltd. | Active, not recruiting --> Completed
    Trial completion
    |
    basroparib (STP1002)
    2years
    Tankyrase-selective inhibitor STP1002 shows preclinical antitumour efficacy without on-target toxicity in the gastrointestinal tract. (PubMed, Eur J Cancer)
    These results demonstrate that STP1002, a novel, orally active tankyrase inhibitor, shows preclinical antitumour efficacy without on-target toxicity in the GI tract. Our data provide a rationale for a clinical trial on STP1002 as a potential tankyrase-targeted drug in patients with APC-mutated CRC.
    Preclinical • Journal • PARP Biomarker
    |
    APC (APC Regulator Of WNT Signaling Pathway) • PARP1 (Poly(ADP-Ribose) Polymerase 1)
    |
    KRAS mutation • APC mutation
    |
    G007-LK • basroparib (STP1002)